Back to news and publications

Strata Oncology Senior Vice President of Clinical Development Kat Kwiatkowski to Participate in Two Panels at Precision Medicine World Conference

Expert panels to examine collaborative solutions in biomarker testing

June 16, 2022

post-thumbnail

June 16, 2022

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that its Senior Vice President of Clinical Development Kat Kwiatkowski, PhD, will participate in two panel discussions at the Precision Medicine World Conference (PMWC) 2022, being held live from June 28-30 in Santa Clara, CA.

Details of the panels are as follows:

Title: Dismantling Barriers to Biomarker Testing Through Collaboration

  • Time: Tuesday, June 28 at 9:00 AM pacific time
  • Participants: Omar Perez, PhD, Head of Medical Diagnostics, U.S. Medical Affairs Oncology, AstraZeneca; Kat Kwiatkowski, PhD Senior Vice President of Clinical Development, Strata Oncology; Jenn Higgins, Vice President, Public Affairs, Guardant Health; Nikki Martin, Director, Precision Medicine Initiatives, LUNGevity Foundation; Laura J. van’t Veer, PhD, Professor of Laboratory Medicine, University of California San Francisco   

Title: Immuno-oncology Biomarkers for Predicting Drug Efficacy

  • Time: Tuesday, June 28 at 11:30 AM pacific time
  • Participants: Ronnie Andrews, President and CEO, OncoCyte; Kat Kwiatkowski, PhD Senior Vice President of Clinical Development, Strata Oncology; Paul Billings, MD, PhD, FACP, FACMGG, Chief Executive Officer and Director, Biological Dynamics

Recordings of the panels will be available afterwards. For more information, visit https://www.pmwcintl.com.

Media Inquiries

Rachel Ford Hutman  rachel@fordhutmanmedia.com 301.801.5540

About Precision Medicine World Conference

Since 2009, the Precision Medicine World Conference (PMWC) has served as the global forum of information, innovation and inspiration for those who dedicate their work to turning the promise of precision medicine into a standard of care reality in the clinic. Partnering with world-class medical luminaries, Stanford, UCSF, Duke, UPMC, and the University of Michigan, PWMC has gathered those from industry, medicine, healthcare, and government to showcase what is possible to achieve, examine the challenges still to conquer, and to provide an environment that engenders collaboration. See past speakers:  https://www.pmwcintl.com/previous-speakers/

In the news

The latest from Strata Oncology

December 1, 2023

Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium

November 8, 2023

Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards

September 11, 2023

Dr. Nair on the clinical utility of Immunotherapy Response Score 

September 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

September 7, 2023

Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer

July 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

July 3, 2023

Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

June 14, 2023

Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid Tumors

June 1, 2023

Evaluation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab (pembro) Clinical Benefit in Patients (pts) with Advanced Solid Tumors

May 2, 2023

Strata Oncology Receives Honorable Mention in Fast Company’s 2023 World Changing Ideas Awards